Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Barbara Ann Karmanos Cancer Institute
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00514215CT.gov Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer | — | Completed | — | — | — |
NCT00030342CT.gov Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer | — | Completed | — | — | — |
NCT00016042CT.gov Fluorouracil and Biological Therapy in Treating Patients With Metastatic Kidney or Colorectal Cancer | — | Unknown | — | — | — |
NCT00006483CT.gov Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung | — | Completed | — | — | — |
NCT00003408CT.gov Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer | — | Completed | — | — | — |
NCT00003181CT.gov Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer | — | Unknown | — | — | — |
NCT00002475CT.gov Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Kidney Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sargramostim (this asset) | Barbara Ann Karmanos Cancer Institute | P2 | BB · 66 |
| Alpha-Interferon | Dartmouth-Hitchcock Medical Center | P3 | BBB |
| Girentuximab | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Nivestim | National Institutes of Health Clinical Center (CC) | P3 | BB |
| Fluorouracilum | Medical Research Council | P3 | BB |
| Etoposide | City of Hope Medical Center | P3 | BB |
| Isocyclophosphamide | City of Hope Medical Center | P3 | BB |
| Lenvatinib | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P4 | BB |
| Adriamycin | Oliver Jonas | P3 | BB |
+42 more in the Kidney Cancer cohort
Other indications for Sargramostim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P3 | BBB · 72 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
| Chronic Myeloid Leukemia | — | P2 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sargramostim in Kidney Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sargramostim-kidney-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →